The guidance follows an FDA public workshop and centres around recommendations for industry on procedures for non-clinical testing and clinical trial design when developing brain-computer interface devices. The aim is to ensure the safety and effectiveness of research output in this field.
Further support for these emerging devices will be carried out by the newly created Emerging Sciences Working Group to observe and report back about the status of this and similar technology.
